120 related articles for article (PubMed ID: 24232915)
1. Understanding internalization of rotavirus VP6 nanotubes by cells: towards a recombinant vaccine.
Rodríguez M; Wood C; Sanchez-López R; Castro-Acosta RM; Ramírez OT; Palomares LA
Arch Virol; 2014 May; 159(5):1005-15. PubMed ID: 24232915
[TBL] [Abstract][Full Text] [Related]
2. The assembly conformation of rotavirus VP6 determines its protective efficacy against rotavirus challenge in mice.
Pastor AR; Rodríguez-Limas WA; Contreras MA; Esquivel E; Esquivel-Guadarrama F; Ramírez OT; Palomares LA
Vaccine; 2014 May; 32(24):2874-7. PubMed ID: 24583002
[TBL] [Abstract][Full Text] [Related]
3. Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.
Malm M; Heinimäki S; Vesikari T; Blazevic V
Clin Exp Immunol; 2017 Sep; 189(3):331-341. PubMed ID: 28407442
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine.
Dennehy M; Bourn W; Steele D; Williamson AL
Vaccine; 2007 May; 25(18):3646-57. PubMed ID: 17339069
[TBL] [Abstract][Full Text] [Related]
5. Internalization and antigen presentation by mouse dendritic cells of rotavirus VP6 preparations differing in nanostructure.
Tamminen K; Heinimäki S; Gröhn S; Blazevic V
Mol Immunol; 2020 Jul; 123():26-31. PubMed ID: 32388275
[TBL] [Abstract][Full Text] [Related]
6. VP6: A candidate rotavirus vaccine.
Ward RL; McNeal MM
J Infect Dis; 2010 Sep; 202 Suppl():S101-7. PubMed ID: 20684688
[TBL] [Abstract][Full Text] [Related]
7. Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.
Blazevic V; Malm M; Arinobu D; Lappalainen S; Vesikari T
Hum Vaccin Immunother; 2016 Mar; 12(3):740-8. PubMed ID: 26467630
[TBL] [Abstract][Full Text] [Related]
8. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles.
Li T; Lin H; Zhang Y; Li M; Wang D; Che Y; Zhu Y; Li S; Zhang J; Ge S; Zhao Q; Xia N
Vaccine; 2014 Apr; 32(17):1921-31. PubMed ID: 24530406
[TBL] [Abstract][Full Text] [Related]
9. Molecular cloning and immunogenicity evaluation of rotavirus structural proteins as candidate vaccine.
El-Senousy WM; Shahein YE; Barakat AB; Ghanem HE; El-Hakim AE; Ameen SM
Int J Biol Macromol; 2013 Aug; 59():67-71. PubMed ID: 23588003
[TBL] [Abstract][Full Text] [Related]
10. Use of recombinant rotavirus VP6 nanotubes as a multifunctional template for the synthesis of nanobiomaterials functionalized with metals.
Plascencia-Villa G; Saniger JM; Ascencio JA; Palomares LA; Ramírez OT
Biotechnol Bioeng; 2009 Dec; 104(5):871-81. PubMed ID: 19655393
[TBL] [Abstract][Full Text] [Related]
11. Nasal immunization of mice with a rotavirus DNA vaccine that induces protective intestinal IgA antibodies.
García-Díaz A; López-Andújar P; Rodríguez Díaz J; Montava R; Torres Barceló C; Ribes JM; Buesa J
Vaccine; 2004 Dec; 23(4):489-98. PubMed ID: 15530697
[TBL] [Abstract][Full Text] [Related]
12. Identification of an immunodominant CD4+ T cell epitope in the VP6 protein of rotavirus following intranasal immunization of BALB/c mice.
McNeal MM; Basu M; Bean JA; Clements JD; Choi AH; Ward RL
Virology; 2007 Jul; 363(2):410-8. PubMed ID: 17337285
[TBL] [Abstract][Full Text] [Related]
13. Intradermal and intranasal immunizations with oligomeric middle layer rotavirus VP6 induce Th1, Th2 and Th17 T cell subsets and CD4
Heinimäki S; Malm M; Vesikari T; Blazevic V
Antiviral Res; 2018 Sep; 157():1-8. PubMed ID: 29935205
[TBL] [Abstract][Full Text] [Related]
14. Particle bombardment-mediated DNA vaccination with rotavirus VP6 induces high levels of serum rotavirus IgG but fails to protect mice against challenge.
Choi AH; Knowlton DR; McNeal MM; Ward RL
Virology; 1997 May; 232(1):129-38. PubMed ID: 9185596
[TBL] [Abstract][Full Text] [Related]
15. Rotavirus VP6 protein mucosally delivered by cell wall-derived particles from Lactococcus lactis induces protection against infection in a murine model.
Temprana CF; Argüelles MH; Gutierrez NM; Barril PA; Esteban LE; Silvestre D; Mandile MG; Glikmann G; Castello AA
PLoS One; 2018; 13(9):e0203700. PubMed ID: 30192869
[TBL] [Abstract][Full Text] [Related]
16. Rotavirus VP6 preparations as a non-replicating vaccine candidates.
Jalilvand S; Marashi SM; Shoja Z
Vaccine; 2015 Jun; 33(29):3281-7. PubMed ID: 26021725
[TBL] [Abstract][Full Text] [Related]
17. Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore.
Aiyegbo MS; Sapparapu G; Spiller BW; Eli IM; Williams DR; Kim R; Lee DE; Liu T; Li S; Woods VL; Nannemann DP; Meiler J; Stewart PL; Crowe JE
PLoS One; 2013; 8(5):e61101. PubMed ID: 23671563
[TBL] [Abstract][Full Text] [Related]
18. [Expression of the main structural antigen VP6 of human rotavirus by recombinant adenovirus and immune responses induced in vivo].
He J; Wang J; Jiang X; Wang D; Wen L; Dong J; Qu J; Hong T
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Jun; 16(2):109-13. PubMed ID: 12196818
[TBL] [Abstract][Full Text] [Related]
19. The interaction of Rotavirus A pig/China/NMTL/2008/G9P[23] VP6 with cellular beta-actin is required for optimal RV replication and infectivity.
Yuan J; Zhang X; Shi H; Chen J; Han X; Wei P; Feng L
Vet Microbiol; 2016 Dec; 197():111-121. PubMed ID: 27938672
[TBL] [Abstract][Full Text] [Related]
20. Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion.
Corthésy B; Benureau Y; Perrier C; Fourgeux C; Parez N; Greenberg H; Schwartz-Cornil I
J Virol; 2006 Nov; 80(21):10692-9. PubMed ID: 16956954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
